Archive for November, 2020
Using a model developed at the Linköping University in Sweden, scientists can now predict the risk of any adverse effects on the bone marrow and blood status of cancer patients undergoing chemotherapy. This study may make it possible to utilize genetic analysis in identifying patients who have a high probability of side effects. The research was reported in “npj Systems Biology and Applications.”
Health practitioners find it difficult to strike a balance between not causing severe side effects during cancer treatment while simultaneously trying to eliminate as many tumor cells as possible. Tumor cells are known to grow in an uncontrolled and rapid manner. For this reason, chemotherapy treatments that are used to manage cancer have been developed to eliminate rapidly growing cells. They also kill normal cells that grow quickly.
These treatments are known to be extremely strong, with cancer patients developing severe side effects, which can result in discontinuation of treatment. For instance, the authors point out that about 25% of patients with lung cancer who get a combination treatment of the drugs carboplatin and gemcitabine experience lethal side effects on the bone marrow when standard treatment is administered. The bone marrow is a sensitive tissue where different blood cell types are created at a rapid rate.
Because it has been determined that genetic factors may have a hand in how an individual responds to these treatments, the researchers of the study looked into genetic signatures and whether they could be used to determine patients who are at a high risk of experiencing serious side effects from treatment. This would allow scientists to adjust treatment to an individual from the beginning of the treatment. That way, those who are a high risk may have another treatment administered while those at a low risk of experiencing these life-threatening side effects can have higher doses administered, which has the potential to have a major impact on the cancer.
The study is a collaboration between researchers in bioinformatics and pharmacogenetics. The researchers determined the DNA sequences of 96 patients who had been diagnosed with non-small cell lung cancer and had been treated with carboplatin or gemcitabine. Whole genome sequencing gives data on millions of genetic variants that may be useful. The purpose of sequencing was to find out if there were gene groups that were connected to the degree of toxicity that the chemotherapy treatment had on different patients’ bone marrow.
A professor at the Department of Biomedical and Clinical Sciences, Henrik Gréen, states that the researchers managed to show that the model they had developed is biologically relevant, in addition to predicting patients’ side effects. However, for the model to be used in clinics, the model must be tested in further studies.
A biotechnology company you should watch is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This Texas-based company focuses on developing new medicines for the treatment of cancers that affect not just the brain but the central nervous system as well.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Using a model developed at the Linköping University in Sweden, scientists can now predict the risk of any adverse effects on the bone marrow and blood status of cancer patients undergoing chemotherapy. This study may make it possible to utilize genetic analysis in identifying patients who have a high probability of side effects. The research was reported in “npj Systems Biology and Applications.”
Health practitioners find it difficult to strike a balance between not causing severe side effects during cancer treatment while simultaneously trying to eliminate as many tumor cells as possible. Tumor cells are known to grow in an uncontrolled and rapid manner. For this reason, chemotherapy treatments that are used to manage cancer have been developed to eliminate rapidly growing cells. They also kill normal cells that grow quickly.
These treatments are known to be extremely strong, with cancer patients developing severe side effects, which can result in discontinuation of treatment. For instance, the authors point out that about 25% of patients with lung cancer who get a combination treatment of the drugs carboplatin and gemcitabine experience lethal side effects on the bone marrow when standard treatment is administered. The bone marrow is a sensitive tissue where different blood cell types are created at a rapid rate.
Because it has been determined that genetic factors may have a hand in how an individual responds to these treatments, the researchers of the study looked into genetic signatures and whether they could be used to determine patients who are at a high risk of experiencing serious side effects from treatment. This would allow scientists to adjust treatment to an individual from the beginning of the treatment. That way, those who are a high risk may have another treatment administered while those at a low risk of experiencing these life-threatening side effects can have higher doses administered, which has the potential to have a major impact on the cancer.
The study is a collaboration between researchers in bioinformatics and pharmacogenetics. The researchers determined the DNA sequences of 96 patients who had been diagnosed with non-small cell lung cancer and had been treated with carboplatin or gemcitabine. Whole genome sequencing gives data on millions of genetic variants that may be useful. The purpose of sequencing was to find out if there were gene groups that were connected to the degree of toxicity that the chemotherapy treatment had on different patients’ bone marrow.
A professor at the Department of Biomedical and Clinical Sciences, Henrik Gréen, states that the researchers managed to show that the model they had developed is biologically relevant, in addition to predicting patients’ side effects. However, for the model to be used in clinics, the model must be tested in further studies.
A biotechnology company you should watch is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This Texas-based company focuses on developing new medicines for the treatment of cancers that affect not just the brain but the central nervous system as well.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Knightscope’s ASRs have completed over one million field hours and are continuing to improve over time based on field experience
- Knightscope designs, engineers, and builds its ASRs in Silicon Valley, continuing to create American jobs in an economy severely impacted by the pandemic
- The company is committed to changing the way public safety and protection are delivered nationwide
- By joining the $39 billion self-storage industry, Knightscope is targeting to become a prominent security provider in the sector, translating into further opportunities for growth
Knightscope, a developer of advanced physical security technologies utilizing fully autonomous robots focused on enhancing U.S. security operations, is committed to helping create peace and maintaining public safety nationwide via the superior technology it develops and deploys. Combining self-driving technology, robotics and artificial intelligence, Knightscope’s Autonomous Security Robots (“ASRs”) provide 24/7/365 security and are currently patrolling five time zones across the United States, assisting in the creation of safer public and private spaces.
The company’s ASRs are a means of physical deterrence, patrolling sites autonomously and providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The collected data is available round the clock through the company’s Knightscope Security Operations Center (KSOC), an intuitive interface that also features 360-degree eye-level HD video streaming, facial recognition, people detection, thermal anomaly detection, automatic license plate recognition, and automatic signal detection.
In a recent video presentation titled “Knightscope: Peace Through Superior Technology,” CEO William Santana Li explained how Knightscope’s ASRs are changing the way protection is delivered across the United States (https://nnw.fm/a9yXy). It is estimated that there are two million police officers and security personnel across the United States for more than 300 million people across the 50 states. Knightscope’s ASRs are helping to bridge the gap, covering more ground with round-the-clock coverage.
In addition to patrolling and peacekeeping, the ASRs have already helped law enforcement and security with the arrests of suspects in crimes that range from armed robbery to hit-and-run accidents. More information about the work Knightscope is doing to fight crime is available at www.Knightscope.com/crime.
The current ASR product offering from Knightscope currently includes a K1 stationary unit, a K3 indoor machine, and the K5 outdoor machine. Since the K5 outdoor machine’s deployment, the City of Huntington Park Police Department has noted significant changes in their calls for service (down 10%), crime reports (down 46%), arrests (up 27%), and citations (down 68%). The data was compiled from June to December 2018, before deployment, and compared to June to December 2019, after deployment.
Since the company’s creation in 2013, several milestones have already been achieved, including:
- Establishing a 15,000-square-foot facility in Mountain View, California, where Knightscope designs, engineers, and builds their proprietary technology;
- Completing more than one million hours in the field, securing contracts across five United States’ time zones; and
- Continuing to hire and navigate the global pandemic without interruptions, despite the current economic and societal disruptions.
Furthering its position in the industry, Knightscope recently signed an agreement with a Southern California storage facility to utilize the company’s ASR technology. Storage units are particularly susceptible to theft and vandalization. Entry into this $39 billion a year industry offers Knightscope tremendous potential for growth (https://nnw.fm/hFUDu).
The long-term vision of Knightscope is to keep an eye on the greater good. The company’s mission is to make the United States of America the safest nation, supporting millions of law enforcement and security personnel across the country.
For more information, visit the company’s website at www.Knightscope.com.
Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button in the lower right corner (it is not a bot) for direct contact with CEO.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced four key additions to the company’s inside and outside sales teams, including directors of Western Regional Sales and Eastern Regional Sales. “We are excited to be introducing additional talent to our sales department,” said Tom Smith, president and interim CEO of Wrap Technologies. “We continue to see a strong pipeline of inbound requests for BolaWrap demonstrations, training and quotes, and many agencies who have previously seen demos or have been trained on the BolaWrap are now beginning to outfit their officers with our device. With 13 distributors across the U.S., covering 49 states and a majority of domestic sales coming through our distribution network, it is important that we continue to grow in our ability to support our distributors and help drive volume.”
To view the full press release, visit https://ibn.fm/vQbef
About Wrap Technologies Inc.
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, on Monday announced revenue of $10.8 million for the fiscal second quarter ended September 30, 2020. “During the fiscal second quarter, we made good progress toward our strategic goals, gained market share, launched innovating new products, added leading partners, and expanded into new growth markets, all while navigating through a challenging COVID environment. Our quarterly growth was impacted as various distributors reduced deliveries and cleared excess inventory built in the prior quarter. Delivery and inventory trends continued to improve throughout the quarter, with order activity reverting to pre-pandemic levels,” said Richard A. Wright, president and chief executive officer of The Alkaline Water Company. “Our fiscal third quarter is off to a strong start, and we are seeing a record month of sales for October. Demand for our lifestyle brands at the retail level remains strong, and revenue grew a healthy 21% during the first half of our fiscal year. According to the October 3 Nielsen’s data, our flagship brand, Alkaline88(R), has been the fastest-growing non-flavored value-added water in the top 10 brands over the last 13, 26, and 52 week period. Our footprint continues to grow nationally, and this quarter alone, we added over 1,000 new store locations for our A88 family of lifestyle brands. We see strong momentum across all our product categories and consider this quarter’s performance to be an outlier. As of early November, inventory at retailers has normalized, driven by our aggressive summer marketing efforts. We believe the actions taken positions us for stronger growth for the balance of this fiscal year and beyond.”
To view the full press release, visit http://cnw.fm/uXUXI
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) has scheduled a teleconference for today to release its third-quarter 2020 financial results and announce key business updates. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics and other industries. The call, scheduled for today, Nov. 17, at 4:30 p.m. ET., will include a presentation followed by a Q&A session. Anyone in North America who is interested may attend the teleconference live by calling 877-407-8033 and using the verbal passcode PBI Third Quarter 2020 Financial Call and Business Update. Those living internationally may also attend by calling 201-689-8033 and using the same passcode. Beginning Wednesday, Nov. 18, a replay of the conference will be available on the company’s website and by phone.
To view the full press release, visit https://ibn.fm/O0QtE
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) has increased its IP stable to 26 patents worldwide with the announcement of its first U.S. patent for its revolutionary Ultra Shear Technology(TM) (“UST”) Platform
- The patent (US 10,823,159) – entitled “System for High Pressure, High Shear Processing of Fluids” – will be the framework of the company’s new instrument line (the BaroShear K45 Nanoemulsification System) to be commercially released in mid-2021
- UST is expected to revolutionize the processing of immiscible liquids into high quality, highly profitable nanoemulsions
- Nanoemulsions are highly sought after in a variety of industries because of their ability to improve stability, appearance, taste, and/or water solubility of retail products (e.g., food, beverages, cosmetics) as well as for the delivery and bioavailability of biopharmaceutical drugs and vaccines
- The legal cannabidiol (“CBD”) industry has been particularly attractive to the company because of its nascent and enormous popularity, leading to projections from multiple sources that it will surge to a $47 billion market by 2025
- Pressure BioSciences expects to deliver on the preorder of its first dozen BaroShear K45 Systems during the first half of next year, which is expected to generate additional revenue for the company of about $3 million, and that is just for the first half of 2021
Pressure BioSciences (OTCQB: PBIO) recently announced the issuance of the first U.S. patent for its innovative Ultra Shear Technology (UST) platform that utilizes ultra high pressure and intense shearing forces to make unique, high-quality nanoemulsions that have enormous use in a wide variety of industries. The announcement brings PBI’s IP patent portfolio up to 26 worldwide and should move the company rapidly towards significantly increased revenue and profitability.
The patent for the company’s trademarked Ultra Shear Technology (“UST”) platform entitled “System for High Pressure, High Shear Processing of Fluids” is the first long-term patent (20-year) for UST in the world, and takes Pressure BioSciences another step closer toward its mid-2021 planned commercial release of the BaroShear K45 System, which will be the company’s first UST-based processing system to reach the market (https://ibn.fm/ozzPZ).
The UST platform was created to revolutionize the process of mixing liquids that normally do not mix, such as oil and water, but without the need for high quantities of chemicals that are all too common in today’s nanoemulsions. The chemically emulsified mixtures of these liquids currently have wide use in everyday products, such as foods, pharmaceutical drugs and nutraceuticals, cosmetics, industrial lubricants and most recently cannabis oil extracts that are becoming increasingly popular with legalization. PBI’s UST processed nanoemulsions are expected to exceed the quality of today’s chemically-produced nanoemulsions, while decreasing the cost of manufacture and minimizing the need for large amounts of added chemicals.
Nano particles offer a large surface area in relation to their volume due to their small size, which provides them with special chemical, physical and biological properties in contrast to bulk matter at normal scale (https://ibn.fm/sJn1N).
While nano particles are currently used in high-quality items like scratch-proof glasses and transparent sunscreens, their medical applications are perhaps of greatest interest. Drug makers look to nano emulsions as a means of transporting medicines to specifically targeted disease cells, such as cancers, reducing damage to nearby healthy ones. Lipid-based nano particles (“LNP”) are increasingly sought after as vaccine carriers for preventative medical purposes as well. PBI’s UST nanoemulsification platform offers the potential to quickly and successfully compete in these existing areas, because of its many advantages over current processes.
The hemp-derived cannabidiol (“CBD”) market’s pursuit of efficient nanoemulsification for superior delivery, absorption, and bioavailability of its oil-based nutraceuticals is also a potentially very lucrative market because changing perspectives toward cannabis worldwide have created a booming nascent industry. Cannabis market research firm BDS Analytics CEO Roy Bingham predicts legal CBD will become a $47 billion market by 2025 (https://ibn.fm/xZllS).
“Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability, and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” Senior Vice President of Engineering Dr. Edmund Y. Ting stated in the company announcement. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level continues to be quite challenging. Importantly, we believe that PBI’s innovative and now patented UST platform can provide the key to commercial success for nanoemulsion products.”
The company has received pre-orders for 12 BaroShear K45 systems, which it plans to deliver during the first half of 2021 for up to $3 million in additional revenue (https://ibn.fm/TgON9). Pressure BioSciences also is in talks with academic organizations and government agencies that have expressed interest in the UST platform for other product and research possibilities, such as an alternative for processing fresh milk, juices, and other dairy products into a long-term stable, room temperature, tasty products.
For more information, visit the company’s website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY product line. In addition, the company’s subsidiary, Soluble Biotech, moved into a new office and lab space and installed new equipment. POAI also signed its first contract with a pharmaceutical company for protein expression and solubility studies, and licensed 71 additional unique ovarian cancer cell lines from Ximbio, the world’s largest nonprofit dedicated to life science reagents of all kinds. “During the third quarter, we continued our work of laying a foundation for our precision medicine business,” said Predictive Oncology CEO Carl Schwartz, MD, in the press release. “We are making steady progress in our Helomics division with the launch of a restructured clinical test offering to clinicians for ovarian cancer. Our project with UPMC-Magee Womens Hospital, analyzing the genomic and drug response profiles of women with ovarian cancer to build predictive models’ terms of therapy response, is close to completion. We are also in discussions with several pharmaceutical companies about partnerships that will monetize our efforts. . . .Management continues to focus the majority of its resources on the company’s primary mission of applying artificial intelligence to precision medicine and to drug discovery. Our approach and the mediums used to replace rats and mice in preliminary cancer studies are working in three of our operating subsidiaries, Helomics, TumorGenesis and Soluble Biotech.”
To view the full press release, visit: https://ibn.fm/Q6jl5
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
A few days ago, Pfizer announced that it had developed a coronavirus vaccine that had proven to be 90% effective in combating the virus in trials. However, to maintain the vaccine’s efficacy, the vaccine needs to be stored and transported at temperatures below -70º Celsius.
An infectious disease and vaccine specialist, Professor Gordon Dougan, from the University of Cambridge, explains that most vaccines are usually stored around or at 4° Celsius. This, he says, is an easy temperature requirement for refrigerated transport. However, the temperature requirements for the coronavirus vaccine, which are extreme, suggest that refrigeration methods that have been custom made/tailored may be needed to ensure the vaccine’s wide distribution. In a recent interview, Dougan also talked about the vaccine’s chain of delivery.
While more details of vaccine transportation haven’t been announced yet, the National Health Service in the UK has announced that it has been preparing for the vaccine delivery. Last week, Simon Stevens, the chief executive of the NHS, admitted that some of the coronavirus vaccine candidates required ultra-cold storage.
However, the strict temperature requirements for the vaccine pose larger challenges for countries in Latin America, Africa and Asia, as their infrastructure is less developed and the climates there are already hotter than in many developed nations.
The World Health Organization estimated that 70% of people globally must be vaccinated to end the coronavirus pandemic. Asia is home to about three-fifths of the world’s population.
Francisco Duque, the health secretary of the Philippines, told Reuters that the 70-degree requirement for vaccine storage was a hefty one, as the country did not have a facility that meets that requirement. He also stating that Pfizer was using new technology and given that they did not have experience with such, the risks could be high.
Dr. Alexander Edwards, a University of Readings’ associate professor in biomedical technology, stated that with all vaccines, making sure that they’re stored, distributed and administered properly is crucial. He added that huge efforts were in progress to make sure that this was possible for new vaccines.
Some reports had suggested that the COVID-19 vaccine required -80º Celsius for storage, hence the need for special storage and distribution. He added that distributors, manufacturers, pharmacists and healthcare professionals as well as medicine manufacturing and distribution networks that deliver vaccine services would be under pressure to do so and that investing in and supporting the sectors where possible would go a long way.
As precision medicine has become the gold standard in the treatment of cancer, Predictive Oncology (NASDAQ: POAI) is a company that you should watch in this space. POAI specializes in harnessing analytics as well as data in order to deliver customized cancer medicines.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD), the parent company of Vocal, a proprietary technology platform for creators of all types, reported its financial numbers and outlined several business milestones achieved during its three-month and nine-month periods ending Sept. 30, 2020. Highlights of the report include Q3 revenues of $425,000, an increase of more than 32% compared to Q2 revenues of $323,000 and a fourfold increase over revenues of $91,000 for the same period last year. The company attributed the growth in revenues primarily to the increase of Vocal+ paid subscribers and the rising price points for Vocal for Brands’ campaigns. Other highlights include the appointment of new board members and executives, uplisting to the NASDAQ Capital Market, the completion of an underwritten public offering resulting in gross proceeds of approximately $7.8 million, and development updates and optimization for the Vocal platform. “Just under four years ago, in December 2016 , we launched our proprietary platform Vocal, with less than 1,000 beta creators and six owned and operated digital communities,” said Creatd founder and CEO Jeremy Frommer in the press release. “Fast forward to today, we have been able to onboard over 800,000 freemium creators who have collectively published over 150 million words on Vocal, and attract nearly 10 million visitors monthly. These accomplishments were achieved with comparatively few development and marketing resources, compared to other privately funded creator platforms. Now, with a significantly strengthened balance sheet, enhanced visibility from our listing on the Nasdaq Capital Market, and the collaboration of a powerful support network, we believe Creatd is prepared to scale revenues and that our Vocal platform is the driving force that will deliver profitability during fiscal year 2021.”
To view the full press release, visit https://ibn.fm/yOkzc
About Creatd Inc.
Creatd empowers creators, brands, and entrepreneurs through technology and partnership. Its flagship technology platform is Vocal; Vocal provides creators of all shapes and sizes, from bloggers to podcasters and more, with best-in-class storytelling tools, safe and curated communities, and the opportunity to monetize their content. With 34 owned and operated communities, Vocal enables creators to connect to their ideal audiences and to partner with the brands that want to reach those audiences. For more information about the company, please visit www.Creatd.com.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). Pending the FDA’s acceptance of the company’s filing, CNS Pharmaceuticals plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021. “Our laser focus from the beginning has been to start the next phase of the investigation of Berubicin for the treatment of this deadly disease as quickly as possible,” said John Climaco, CEO of CNS Pharmaceuticals. “Our team has worked tirelessly for the past year, making several inroads on our manufacturing and clinical efforts to achieve this important milestone. We believe we are optimally positioned to continue to execute our plan and initiate our Phase 2 trial in the first quarter of 2021. We continue to build on the positive results Berubicin demonstrated in the Phase 1 study in high grade gliomas and look forward to advancing its clinical development in these patients, with the end goal of addressing the unmet medical need of better treatment for patients diagnosed with GBM.”
To view the full press release, visit http://ibn.fm/IN4x8
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to stockholders from its CEO Dr. James Woody. The letter addresses the closing of the merger with KBLM Merger Corp IV, which resulted in 180 Life Sciences now operating as a stand-alone publicly traded company with its common stock listed on the Nasdaq Capital Market under the symbol “ATNF.” In the update, Dr. Woody shares a little about himself and the world class team of scientists, physicians, and executives that now comprise the 180 Life Sciences management team and board of directors. He also discusses the company’s drug pipeline and plans moving forward, including what lies ahead and anticipated critical milestones. “I started my career in biotech as the Chief Scientific Officer and Senior Vice President of Research and Development at Centocor, where I led the team responsible for developing Remicade, the first of the TNF (tumor necrosis factor) inhibitor biologics,” Dr. Woody states in the letter. “This was in collaboration with Prof. Sir Marc Feldmann, one of the founders of 180 Life Sciences and the current Co-Chairman of the Board of Directors. Marc and I go back a long way, to the late 70s. Remicade was a breakthrough product, it was the first anti-TNF to show dramatic efficacy and triggered the ‘antibody revolution.’ According to a report in FiercePharma, Remicade sales topped $7 billion USD in 2016 and were $5 billion in 2019.”
To view the full press release, visit http://ibn.fm/HExHn
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be submitting a protocol amendment request to the U.S. Food and Drug Administration (“FDA”) for its Phase 2b OPTION 2 trial of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The proposed amendment requests the potential to add a study arm that uses an immediate-release MS1819 capsule. If approved, AZRX will be able to compare data from the existing arm that uses enteric (delayed-release) capsules with data from the new arm. Everything else regarding the study, including trial objectives, endpoints and statistical analysis, will remain the same. “We are pleased to announce that our OPTION 2 trial is well ahead of schedule and almost fully enrolled without any safety issues being observed,” said AzurRX chief medical officer James Pennington, MD, in the press release. “As this trial progresses, we believe there may be significant clinical value in adding a study arm that uses our immediate release capsules. Our intention is to identify the optimal delivery method and potentially provide additional scientific support and optionality for MS1819.”
To view the full press release, visit http://ibn.fm/Nj1Am
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, New York, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Globally it is estimated that 70,000 people suffer from CF, with half the population in the United States
- The global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion by 2026
- AzurRx BioPharma’s MS1819, currently undergoing clinical trials, is a promising therapy for severe exocrine pancreatic insufficiency in patients with cystic fibrosis
While still a relatively rare genetic disease, cystic fibrosis (“CF”) remains a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. This is why the need for innovative and effective therapies for the treatment of CF-associated ailments, such as AzurRx BioPharma’s (NASDAQ: AZRX) drug candidate for exocrine pancreatic insufficiency, is constantly growing.
According to Allied Market Research, the demand for effective treatment options is driving a global expansion of the CF therapeutics market. Further driven by the availability of personalized drug therapy and molecular prosthetics, the global CF therapeutics market is expected to reach $9.3 billion by 2026, from $4.62 billion in 2018 (https://ibn.fm/E8kIz).
Cystic fibrosis is a progressive, genetic disease characterized by persistent lung infections and limited breathing ability over time as well as significant digestive problems. It is caused by a mutation of the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene making it unable to transport salts across cell membranes, resulting in the buildup of thick and sticky mucus in different organs and tissues.
In the lungs, the mucus clogs the airways and traps germs, which leads to infections, respiratory failure, inflammation, and other complications. The pancreas is also affected by the buildup of mucus, which prevents the release of digestive enzymes. These digestive enzymes are key to absorbing food and nutrients, often leading to malnutrition and poor growth (https://ibn.fm/ucQP4). Many patients with CF have a weak immune system and are also at a higher risk of developing other severe health conditions, such as hypersplenism, diabetes, cirrhosis, osteoporosis and arthritis.
Globally, it is estimated that 70,000 people suffer from cystic fibrosis, but the incidence of the disease varies significantly across the globe, as prenatal and newborn screening for CF is not standard practice. The U.S. has one of the highest incidence rates with about 35,000 diagnosed cases, according to the
Centers for Disease Control (https://ibn.fm/YBzVq). A World Health Organization report indicates that the incidence of CF in the U.S. is one in every 3,500 births and slightly higher in the European Union, where one in 2,000-3,000 newborns are affected (https://ibn.fm/DEFzu).
While the condition is largely underdiagnosed in Africa and Asia, a recent study out of India showed that the prevalence of cystic fibrosis could be higher than previously believed. Research conducted by Sir Ganga Ram hospital in Rajendra Nagar, Delhi, and published in the BMC Medical Genetics of London, indicated that one in 2,000 newborns in the populous Asian nation may be at risk of being born with CF, after finding a high carrier frequency of 4.5% in male and female subjects (https://ibn.fm/fCIZ4).
AzurRx’s MS1819 Showing Promising Results
Technological advances have greatly increased the lifespan for those suffering from CF, especially since the 1950s when children with CF rarely made it to elementary school age (https://ibn.fm/5m5XR). The median age of survival for a CF patient is now around 47 years, with many patients living into their 60s (https://ibn.fm/66lO7).
Due to the efforts of companies such as AzurRx BioPharma, the lifespan and quality of life of CF patients could be further improved. AzurRx’s lead product is MS1819, a recombinant lipase that could potentially change the treatment of exocrine pancreatic insufficiency (“EPI”) in CF and chronic pancreatitis (“CP”) patients.
The company is currently undergoing Phase 2 trials and pursuing approval through parallel monotherapy and combination therapy pathways. The two current clinical trials for MS1819 in CF patients are a Phase 2b Option 2 monotherapy trial and a Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (“PERT”), the current standard of care. Preliminary results from the combination trial have shown clinically meaningful improvements in subjects, with no adverse safety events.
The company believes that due to its safety and efficacy, MS1819 has the potential to improve the quality of life and help achieve healthier nutrition for many patients suffering from severe EPI. AzurRx is scheduled to complete treatment of all patients and announce top line data from both clinical studies in 2021.
For additional information, visit www.AzurRx.com or contact the following:
AzurRx BioPharma, Inc.
Martin Krusin
Vice President for Corporate Development
Phone: (646) 699-7855
info@azurrx.com
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
According to a systematic review that was reported in Therapeutic Advances in Psychopharmacology, psychedelic drugs such as LSD and mescaline decrease the recognition of negative facial expressions. Generally, the main facial expressions characterizing basic human emotions are happiness, sadness, surprise, disgust, fear and anger. The psychedelic substances do this by adjusting the amygdala’s activity, which is the region of the brain that drives a person’s flight or fight response.
A postdoctoral fellow at the University of Sao Paulo, Rafael Guimarães dos Santos, who is the study’s author, explained that they’d been looking into the effects of ayahuasca on humans for the past decade and a half. They discovered that its effects, as well as those of other serotonergic hallucinogens like psilocybin and LSD, involve changes in emotional processing.
The researchers explored 5 prior studies on psilocybin and 2 prior studies on LSD. All 7 experimental studies assessed facial expression recognition.
In the review, the researchers explained that the most consistent finding was that both psilocybin and LSD reduce negative emotions recognition and modified the amygdala’s activity to these stimuli. While this effect corresponded with anti-depressive effects in patients who are depressed, it was difficult to make a conclusion on whether this result had any clinical relevance, given that this had been observed in one study with an open-label design.
Prior research had also shown that people who suffered from depression and anxiety disorders usually have a bias in favor of negative facial emotion recognition. In theory, the reduction of negative facial emotion recognition may help treat these conditions.
Santos stated in an interview that changing emotional processing through adjusting recognition of facial emotions could be among the mechanisms involved in ayahuasca and other serotonergic hallucinogens’ therapeutic potential.
The researchers also observed in the review that the studies that had been reviewed demonstrated that one dose or a few doses of psilocybin or LSD were associated with an altered pattern of negative emotion recognition that may be interpreted as beneficial. This is because several of these studies showed that these moderations correlated with increases in antidepressant effects and/or anxiolytic and positive mood.
Santos noted that despite this, his team of researchers was only able to find a few studies on the topic, whose sample sizes were small. Excluding Santos, the team of researchers included Jaime E. C. Hallak, Giordano N. Rossi, José Carlos Bouso, José Alexandre S. Crippa, Flávia L. Osório and Juliana M. Rocha.
Cybin Inc. (NEO: CYBN) is one life science company you should watch. It specializes in developing pharmaceutical psychedelics products as well as addressing the needs of the functional mushrooms market.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
November 17, 2020
Gage Cannabis Co. today announced that it will offer adult-use (recreational) marijuana sales at its flagship store in Ferndale, Michigan. Located at 1551 Academy St., the store has been open for medical card holders since September 2019. The company opened its first adult-use retail location in Adrian, Michigan in July 2020 and its second earlier this month in Lansing, Michigan. “We have been looking forward to this day since we opened our doors in September 2019,” said Mike Finos, president and executive vice president of operations at Gage Cannabis. “We are excited to extend the Gage experience to anyone ages 21 and over. Metro Detroit is home to our biggest consumers, and we’re ready to provide the community with quality products and a unique customer experience.”
To view the full press release, visit https://nnw.fm/i7VNg
About Gage Cannabis Co.
Gage Cannabis is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 “Class C” cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries). To learn more, please visit www.GageUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://nnw.fm/GAGE
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
November 17, 2020
Rritual, a plant-based consumer brand, is a natural wellness innovator positioned at the heart of a fledgling industry rife with opportunity. According to Grand View Research Inc., the overall functional foods market is projected to reach $275.77 billion by 2025 (https://nnw.fm/NO6n2), and the demand for nutraceuticals and functional foods is now expected to surge even more than anticipated. Rritual has entered the market with its flagship product line of certified organic mushroom and adaptogen elixir mix powders. The company’s non-psychoactive wellness elixirs include a Chaga blend designed to boost immunity, a Lion’s Mane blend designed to support cognitive function and brain health, and a Reishi blend to help the body fight anxiety. “The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research,” Rritual President Dr. Mike Hart said of the product launch. “Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects.”
To view the full article, visit https://nnw.fm/Lx94H
About Rritual Superfoods Inc.
Rritual is a plant-based consumer wellness brand dedicated to creating simple, pure, yet effective plant-based health products that are mindfully designed to also facilitate the practice of daily self-care, so that the health of the whole body, mind & spirit is supported. Backed by a leading team of scientists, doctors, nutritionists, and experts across the wellness space, Rritual has entered the market with their flagship collection of certified organic Mushroom and Adaptogen Elixir Mix powders, offering products made with the most-popular mushrooms and in the top need-state health categories: Lion’s Mane Focus, Reishi Relax, and Chaga Immune. For more information, visit the company’s website at www.WeAreRritual.com or visit Twitter, Instagram, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to Rritual are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Research carried out by the School of Public Health and Social Policy at the University of Victoria along with the Canadian Institute for Substance Abuse Research revealed that people who used medical marijuana experienced a decline in their alcohol consumption.
The study involved 1,000 medical marijuana patients in Canada and examined them on their habits, which included questions on their alcohol consumption. The study’s findings revealed a decline in alcohol use.
The study asserted that marijuana can affect the use of other psychoactive substances, including illicit drugs, tobacco, alcohol and prescription medications. However, little research has been conducted that looks into the factors linked to these changes in substance use.
During the study, 18% of the individuals who were polled reported that they abstained from alcohol, 85% claimed that they decreased the drinks they consumed every week and 44% reported a decline in the frequency of their alcohol consumption as they used medical marijuana.
From the Canadian medical marijuana program, a sample of 2,102 individuals provided their data, with each individual giving answers based on their medical marijuana use throughout the study and how it affected their alcohol consumption. More than 970 respondents who used alcohol at least 10 times over a year before starting to use medical marijuana were also included in the study. The researchers then assessed retrospective data on amount of alcohol and the frequency of use before and after medical marijuana initiation.
It is estimated that about 107 million people around the globe suffer from alcohol use disorder. This is a physical and mental addiction that’s common. The use of marijuana/medical marijuana to help decrease alcohol use is good news for many. Additionally, the WHO reports that marijuana is 114 times safer than alcohol, with alcoholism killing 3 million individuals around the globe annually.
The study findings suggest that the use of medical marijuana may be linked to reductions in alcohol intake and cessation among medical marijuana patients. Liquor is the most common recreational substance in North America, and it has high rates of mortality, morbidity and criminality as a result of its use. The authors of the study claim that these findings may bring about better health outcomes for medical marijuana patients and improve general safety and public health as well.
While this is only one study that looks into the link between the use of alcohol and medical marijuana, it may be the key to more research that supports marijuana treatment as a way to keep off liquor.
A company worthy of your attention in the cannabis industry is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). The company focuses on using innovative proprietary electrolysis processes to make perfectly balanced alkaline water as well as CBD-infused eats and drinks.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
- Survey suggest over 60% of millennials willing to accept lower returns if an investment is sustainable, 83% considering transitioning entire pension into sustainable portfolio
- SGTM produces environmentally beneficial products using natural waste created by hurricanes and storms while preventing burdens on municipal landfills
- SGTM recorded 794% increase in revenue and 4,817% increase in gross profit compared to all of 2019, preparing for future uplisting
Discretionary spending across almost all sectors has taken a dive in recent months as the global recession deepens. Despite the negative performance across many consumer goods and service sectors, some businesses continue to survive – and even thrive. Among them is Sustainable Green Team (OTC: SGTM), a leading provider of solutions for tree and storm waste disposal that turns problems into profits through the transformation of natural waste into products that benefit the environment.
Awareness around sustainable investing appears to be increasing, particularly among millennials who appear to be driving the movement. A recent survey suggests that over 60% of investors within this age group would accept lower returns if an investment is ethical while 83% are considering transitioning their entire pension into a sustainable portfolio (https://ibn.fm/zDXtA).
“You do not have to sacrifice returns when investing in a socially responsible portfolio,” said Jamie Broderick, Impact Investing Institute & former UK CEO of UBS Wealth Management. “There are several different categories along the spectrum of capital, and you can choose how you’d like to invest in line with your values, whether in line with market returns, or on a concessionary basis.”
SGTM provides an opportunity for investors to take part in a sustainable business with significant growth potential. Through its subsidiaries, the company provides tree services that include debris hauling, debris removal, biomass recycling, mulch and playground surface material manufacturing, product packaging and sales. Founded in sustainability and based on vertically integrated operations, the company takes its role as a steward of the environment seriously by diverting this natural material from landfills and transforming it into a variety of organic, attractive, next-generation products that benefit the natural landscape.
SGTM’s expansion plans include organic growth strategies, national partnerships and strategic acquisitions. Following a busy storm season that included Hurricane Laura relief efforts, the company was awarded a string of contracts with large companies that included The Kroger Co., Circle K, 7-Eleven, Old Castle Lawn & Garden, Menards Inc., and many more. The company has commenced the FORM-10 process to become fully reporting and, in anticipation of a future uplisting, disclosing a massive 794% increase in revenue and a 4,817% gross profit increase in the first half of 2020 when compared to all months in 2019 combined (https://ibn.fm/0EG3C).
Along with its stellar financial results, SGTM’s impressive overall performance is a testament to the expertise of its management, bolstered by over 40 years of next-level experience across all the company’s verticals. It may not make front page news or create a buzz like electric vehicles or biotech innovation, but the work carried out by SGTM makes a positive impact that directly improve the lives of citizens in the communities the company serves – all while sharing the profits with its loyal group of investors.
To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/l1Pgk.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announced that it has engaged Anthony L.G. PLLC to initiate the FORM-10 process to become fully reporting, uplist and assist with all SEC legal matters. According to the update, the engagement was made shortly after the company’s wholly owned subsidiary, Mulch Manufacturing, expanded its 2021 mulch contracts with Circle K convenience stores, a subsidiary of Alimentation Couche-Tard Inc. (OTC: ANCUF). “We have communicated with many firms since our audit completion to see whom would be best suited for our team, shareholders, and transpire our vision,” said SGTM’s CEO and Director Tony Raynor. “After communicating with Laura Anthony and doing our due diligence, our team feels more confident than ever on achieving our ultimate goal to be listed on the NASDQ to maximize exposure and greater value.”
To view the full press release, visit http://ibn.fm/qSXnY
About Sustainable Green Team Ltd.
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://ibn.fm/NYk36
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights to publicly traded companies through Sequire, announced results for the three months ended September 30, 2020. Among the highlights, the company reported $2.6 million in total revenue for Q3, which represents 161% year-over-year (“YoY”) and 124% sequentially quarter-over-quarter (“QoQ”) growth. “As the Sequire platform continues to grow and adapt to customer needs, we are seeing a tremendous increase in our recurring revenue stream,” said Chris Miglino, founder and CEO of SRAX. “Sequire is changing the way public issuers interact with and engage their investors, and it shows. We are pleased to report our first quarter of positive EBITDA from our Sequire segment.”
To view the full press release, visit http://ibn.fm/po8vK
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will participate in two upcoming investor conferences. According to the update, Processa will participate in one-on-one meetings at the Craig-Hallum Alpha Select Virtual Conference on Tuesday, Nov. 17, 2020, and the Benchmark Annual Discovery 1×1 Investor Virtual Conference on Wednesday, Nov. 18, 2020. Interested parties should contact their conference representative or James@HaydenIR.com to schedule a one-on-one meeting with management.
To view the full press release, visit http://ibn.fm/biHn2
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Third Quarter 2020 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website) approximately one day after the teleconference.
The teleconference will include a Company presentation followed by a Question & Answer period.
Date: Tuesday, November 17, 2020.
Time: 4:30 PM Eastern Time (ET).
To attend this teleconference, live by telephone: Dial-in: (877) 407-8033 ( North America ); (201) 689-8033 (International). Verbal Passcode: PBI Third Quarter 2020 Financial Call & Business Update.
For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, November 18 , 2020. The replay will be accessible via telephone and the Company’s website for 30 days.
Replay Number: (877) 481-4010 ( North America ); (919) 882-2331 (Int’l); Replay Passcode: 38901.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com
- CEO expects results that will “build the stock and raise the stock price”
- POAI focused on positioning TumorGenesis kits to manufacturers
- Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research
During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics.
“I’m very encouraged. I think we’re moving right along. Things never go as fast as we would like them, and it can be very frustrating at times,” Schwartz stated. “We have a lot going on, and we’re working hard on our goals. . . . We expect results that will be advantageous to the company and that will build the stock and raise the stock price.”
During the interview, Schwartz noted that the original purpose of TumorGenesis was to develop a lab media to replace rats and mice in scientific industries as well as the testing of tumors. The company has succeeded in developing the first media: ovarian cancer.
“This media, which, as I said, replicates the body, fools the tumor into thinking it’s still in the body,” Schwartz explained. “Its reactions are very, very similar to what it would have done had it been in the body. Now the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That’s coming along handsomely.”
Schwartz also talked about POAI’s newest subsidiary, Soluble Biotech, which is essentially the combination of two labs. “We moved them now into a research park,” he said. “We quadrupled the space that they have, and they have the latest in equipment. The technology used by Soluble is proprietary. These machines that we have were developed some time ago and are the only machines of their kind. In the determination of solubility of products, they work wonders in that area. We expect, going forward, that they’ll get a number of contracts.”
Finally, Schwartz noted that POAI has positioned Helomics to compete in the marketplace. “The original basis of Helomics . . . was that physicians or hospitals would send their tumors to this company, and they would test the tumors with the known therapies of the day,” he said. “In that process, [Helomics] accumulated over 150,000 tumors covering over 137 different cancer.”
Schwartz noted that Helomics currently has the largest database of its kind in the world, and through its subsidiary, POAI brings cutting-edge technology to cancer research and works with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how specific tumors may respond.
“With that data, and the fact that we’ve sequenced these tumors, we have shown that we can provide quality information to anyone who needs it,” he continued. “There’s a lot going on at Helomics. We think we’ve validated the company. We’ve got assets that are one-of-a-kind in the world, and we think we are on our way to where we wanted to be when we first purchased this company a couple of years ago.”
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE), a global technology and value-added solutions group that supports electronic payments acceptance in a multichannel environment including point of sale (“POS”), e-commerce and mobile devices, today announced its financial results for the third quarter ended Sept. 30, 2020. Among the highlights for the quarter as compared to the same period in 2019, Net Element reported an increase in total transaction volume to $956.2 million versus $953.7 million, a decrease in net revenues to $16.7 million versus $16.8 million, as well as an increase in North American Transaction Solutions revenue to $16.07 million versus $15.9 million. “We continue working diligently in an effort to finalize the Mullen merger for the benefit of our shareholders,” said Oleg Firer, executive chairman of Net Element.
To view the full press release, visit http://ibn.fm/i7NfQ
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement (the “Merger Agreement”) to merge with privately-held Mullen Technologies Inc. (“Mullen”), a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). That contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visit www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
At the moment, many countries are pinning their plans of recovering from the pandemic-induced economic downturn on investments that will be directed towards developing or deepening green technologies, such as electric vehicles and renewable energy. However, the catchy phrases being flashed around will not help the world operate more sustainably if careful planning isn’t directed towards making the leap workable in the long term.
For example, making the switch to renewable forms of energy, such as solar and wind energy, to quickly can leave economies at the mercy of the fickle weather. This could have devastating consequences when not enough sunlight is available to capture solar power or when wind strengths are so low that wind turbines are unable to work.
Such supply shocks can easily make renewable energy prohibitively expensive, and that would make the dream of 100% sustainable energy undesirable and even unworkable.
A sudden total switch would also reveal how deficient countries around the world are in regards to mass storage capacity for the energy generated within the windows when ample sunlight or a sufficiently strong wind exists to generate electricity.
So, what is the way forward?
Now is the time to be real about the practical issues that may impede the dream of delivering or using sustainable technologies. For example, the public in many parts of the world isn’t yet fully sold on switching to electric vehicles because of a valid concern about the limited charging infrastructure available.
In the spirit of confronting head-on the challenges to a sustainable future, Cranfield University is working with the UK government to establish an app that will facilitate peer-to-peer trading of energy needed to charge EVs. The plan is to link EV owners with excess battery power to those who need it. The exchange can take place at cafes or charging stations which are privately owned.
Another example of the way in which the anticipated challenges of switching to renewable energy can be addressed is by developing drones that can enable tech teams to remotely monitor offshore wind farms. Currently, it is expensive and inefficient to send crews in chartered ships to provide information and to monitor these wind farms. By using drones to inspect the wind turbines, costs can go down and system reliability can be improved.
Such efforts can ensure that consumers can adjust their behavior and make better choices so that the way they collectively live undergoes a paradigm shift to more sustainable technologies.
Net Element (NASDAQ: NETE) is a company you ought to watch in the green energy space. Early in August, this global financial solutions firm announced that it was merging with a California-based EV manufacturer called Mullen Technologies Inc. All eyes are on how the new entity will fare in the electric vehicle space.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Researchers have found a genetic signature that can forecast whether cancer is likely to metastasize or spread in the early stages of localized prostate cancer. The signature can also predict whether the disease will respond to anti-androgen therapy. In addition, the new signature may be beneficial in helping evaluate the disease’s response to treatment as well as creating new treatments to treat or avert the advanced stages of prostate cancer. This groundbreaking study was reported in “Nature Cancer.”
A professor of cell biology and pathology in Columbia University’s Irving Medical Center, Cory-Abate-Shen, senior author of the study, states that if scientists could know beforehand which patients would develop metastases, this would enable them to begin treatments earlier and treat the disease more aggressively. The information would also be valuable for patients whose cancer is likely to remain restricted to the prostate as they could be spared unnecessary therapy.
In the United States, prostate cancer is the second-leading cause of cancer death in men. This year, it is estimated that approximately 33,330 men will succumb to the disease. Most prostate cancers do not spread to other areas, remaining in the prostate. These cancers can be managed successfully by local therapy such as radiotherapy or surgery or surveillance. Their five-year survival rates are over 99%. However, once prostate cancer spreads, survival rates reduce to about 30%, and the cancer is said to be incurable.
Associate research scientist in therapeutics and molecular pharmacology at Columbia University, Juan M. Arriaga, lead author of the study, states that it’s difficult to know which cancer is which, a problem that impacts the current tests being used. This challenge can lead to overtreating of cancers that grow slowly and that may not have spread; it can also contribute to missing aggressive cancers that could have been treated in good time.
The researchers used a mouse model to identify a more precise technique of forecasting advanced prostate cancer. They discovered that the molecular profile of bone metastases was different when compared to the molecular profile of primary tumors. This enabled the researchers to determine 16 different genes that prompt localized prostate cancer to spread.
The researchers note that the genetic signature, i.e., META-16, was extremely effective at predicting the time the disease would start spreading and if it would respond to anti-androgen therapy. This therapy is used to suppress the male hormone as it stimulates tumor progression. The new signature may, in theory, be used to create therapies that prevent metastatic prostate cancer. At this stage, the researchers are improving the test, with the hope that they’ll assess it in a future clinical trial.
DarioHealth Corp. (NASDAQ: DRIO) is a specialist in digital therapeutics and is a company you should watch. DarioHealth touts the use of artificial intelligence to deliver personalized user experience regarding its smartphone-based, chronic-disease management.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Creatd, Inc. (Nasdaq CM: CRTD) (“Creatd” or the “Company”), the parent company of Vocal, a proprietary technology platform for creators, today reported financial results for its three and nine-month periods ended September 30 , 2020. The Company accomplished several milestones and financial goals during the third quarter of 2020, including up-listing to the Nasdaq Capital Market, as it readies its operations to deliver on its accelerated growth trajectory.
Key Third Quarter 2020 Highlights:
- Reconstituted Creatd’s Board of Directors and appointed several new members:
- Mark Standish , former co-CEO of RBC Capital Markets, was appointed Chairman of the Board in July as well as Chairman of the Audit Committee.
- Mark Patterson , co-founder of a multi-billion private equity firm MatlinPatterson Global Advisors, joined the Board of Directors in July and was appointed Chairman of its Compensation Committee.
- Laurie Weisberg , technology and data marketing executive (previously Chief Sales Officer of Intent, Chief Revenue Officer of Thrive Global and member of the executive leadership team of Datalogix through its $1.2 billion acquisition by Oracle) joined the Board of Directors in July.
- LaBrena Jones Martin , a highly seasoned corporate and securities attorney (previously with SEC, E.F. Hutton, Shearson, Lehman Brothers, and RBC), joined the Board and was appointed Chair of its Nominating and Corporate Governance Committee, subsequent to the third quarter of 2020.
- Up-listed to the Nasdaq Capital Market on September 11, 2020 , changed its name to Creatd, Inc., and effectuated a 3-for-1 reverse stock split.
- In connection with the Nasdaq up-listing, the Company completed an underwritten public offering resulting in gross proceeds of approximately $7.8 million .
- In September, the Company announced the appointment of Laurie Weisberg as Chief Operating Officer, in addition to her responsibilities as a member of the Board of Directors.
- Development updates and optimization the Vocal platform in anticipation of the continuing increases in visitor volume and platform activity; upgraded internal management systems.
- Surpassed third quarter revenues guidance by over 6%, generating approximately $425,000 , an increase of 32% over the second quarter 2020 and a more than four-fold increase compared to third quarter 2019. Management anticipates that fourth quarter revenue growth will match, if not exceed the growth achieved in the third quarter.
- Reduced total liabilities from $15.5 million to $3.3 million during third quarter 2020 through conversion of notes and payables into equity as well as a $3.6 million cash payment towards multiple accrued payables and short-term debt.
- Vocal Key Metrics:
|
9-30-2019
|
6-30-2020
|
9-30-2020
|
Current as of 11-15-2020
|
|
Content Creator Accounts – Freemium
|
485,780
|
642,539
|
714,165
|
810,000
|
|
Vocal+ – Paid subscriber Accounts
|
250
|
2,300
|
4,600
|
7,500
|
|
Vocal+ Subscriber Acquisition Cost (SAC)
|
$1,000
|
$350
|
$180
|
$170
|
Commenting on the third quarter, Jeremy Frommer , Creatd’s founder and CEO, said, “Just under four years ago, in December 2016 , we launched our proprietary platform Vocal, with less than 1,000 beta creators and six owned and operated digital communities. Our goal was to create a best-in-class technology platform that made it easy for creators of all types to share their stories and their experiences, get discovered, and be rewarded for their passions. Core to Vocal’s design are its storytelling tools. With its unparalleled editor, the creator has the ability to integrate already-published rich media such as videos, songs, and podcasts to reach niche communities and engage with their ideal audiences.”
Frommer continued, “Fast forward to today, we have been able to onboard over 800,000 freemium creators who have collectively published over 150 million words on Vocal, and attract nearly 10 million visitors monthly. These accomplishments were achieved with comparatively few development and marketing resources, compared to other privately funded creator platforms. Now, with a significantly strengthened balance sheet, enhanced visibility from our listing on the Nasdaq Capital Market, and the collaboration of a powerful support network, we believe Creatd is prepared to scale revenues and that our Vocal platform is the driving force that will deliver profitability during fiscal year 2021.”
Creatd reported third quarter 2020 revenues of $425,000 , more than four-fold increase compared to revenues of $91,000 for the same period in the previous year and a 32% increase from the $323,000 in revenues reported for the second quarter of 2020. Of note, second quarter revenues of 2020 were 10% greater than the first quarter of 2020. The significant year-over-year increase in revenues is predominantly due to steady growth of Vocal+ paid subscribers and the rising price points for Vocal for Brands’ campaigns. Vocal+ came out of beta in early 2020 and, with little budgeted for marketing, grew to over 4,500 paying subscribers by the end of the third quarter. Now, with an increase in marketing as a result of the Company’s equity financing in mid-September, Vocal+ subscribers are increasing in excess of 100 new subscribers per day, and maintaining current levels, should surpass the Company’s goal of reaching 10,000 paid subscribers by year end. As the number of paid Vocal+ subscribers continue to increase, subscriber acquisition costs (SAC) are expected to continue to decline. Currently, acquisition costs total less than $170 per subscriber, compared to costs of $350 per subscriber at the end of second quarter 2020 and over $1,000 per subscriber only one year ago at the end of third quarter 2019.
Vocal for Brands, which generated approximately 39% of the Company’s third quarter revenues, is experiencing growth in both brand customer count as well as individual campaign price increases. Vocal for Brands grew revenues nearly 100% since the second quarter, with an over 25% increase in average contract price. Managed Services, vis a vis the Seller’s Choice agency, accounted for roughly 43% of revenues generated during the quarter. While Managed Services revenues were essentially flat quarter over quarter, this business line saw an increase in new clients towards the end of September, which is expected to impact revenue starting in the fourth quarter, historically the best quarter for this business line.
Operating expenses for the three months ended September 30, 2020 totaled approximately $7,449,000 . This is over four times the operating expenses reported in third quarter 2019 and over two times that of the second quarter 2020. The increase in operating expenses primarily reflects non-recurring charges attributed to the Nasdaq up-listing and related financing activities, totaling approximately $1,200,000 , as well as $3,600,000 related to 400,000 performance-based stock options granted to management, that was required to be expensed entirely during the quarter. These performance options represent over three years of catch-up options for 13 members of the management team, and are expected to vest in April 2021 . Going forward, the Company expects operating expenses to decrease materially, slightly offset by a measured increase in support staff focused on revenue growth. Subsequent to quarter-end, Creatd increased its sales team from two to eight individuals, including several senior professionals with long-standing brand relationships. During the three-month period ended September 30, 2020 , the Company incurred a loss from operations of $(7,024,000) . This compares to a loss from operations of $(1,657,000) during the same period last year and a loss of $(3,535,000) during the second quarter 2020.
The Company incurred other (non-operational) expenses of $6,552,000 in the third quarter 2020, compared to $277,000 in the third quarter 2019, and $607,000 in the second quarter 2020. The increase in third quarter other (non-operational) expenses was due to an increase in non-recurring, non-cash charges for accretion of debt discount and issuance costs totaling approximately $6,371,000 , offset by other income of $438,000 related to a cash rebate the Company receives from its research and development subsidiary in Australia .
The Company reported a comprehensive loss of approximately $(13,570,000) , or $(3.20) per share, for the three months ended September 30, 2020 , compared to the previous year’s third quarter comprehensive loss of approximately $(1,934,000) , or $(0.65) per share, and a comprehensive loss of $(4,161,000) , or $(1.29) per share for the second quarter 2020.
For the nine months ended September 30, 2020 , the Company reported revenues of approximately $1,040,000 compared to revenues totaling approximately $133,000 for the same period in 2019. With the continued development of our Vocal technology platform, a vastly improved balance sheet, and a newly expanded seasoned sales team, management anticipates reporting accelerated quarterly revenue growth for the foreseeable future.
Operating expenses for the nine months ended September 30, 2020 totaled $13,426,000 as compared to $4,897,000 for the nine-month period ended September 30 , 2019. The increase in operating expenses predominantly reflects one-time expenses related to the Nasdaq up-listing, the underwritten public offering, and the debt conversion, as well as $1,400,000 of non-cash charges related to employee option exchange for stock during second quarter and $3,600,000 in three-year catch-up performance-based stock options granted to 13 members of the management team during the third quarter. During the first nine months of 2020, our average monthly cash burn was approximately $559,000 per month, in line with previous years. Management expects this number to remain steady during the course of fiscal year 2021, barring any consideration of growth opportunities that could require additional expenditures in this period.
Interest expense during the first nine months of 2020 totaled $1,379,000 compared to $329,000 during the same period of 2019. Creatd reported a comprehensive loss for the nine months ended September 30, 2020 of $(20,726,000) or $(5.91) per share, which included a non-recurring, non-cash charge of $6,698,000 related to debt conversion to equity. This compares to a net loss of $(5,400,000) or $(2.05) per share for the same period in 2019. Net cash used in operating activities during the first nine months of 2020 totaled $5,032,000 compared to $4,708,000 for the same period in 2019. Management expects future financing specifically to scale its customer acquisition and marketing campaigns.
Company Reduces Current Liabilities from $14.9 Million to $2.7 Million During Third Quarter 2020
On September 30, 2020 , the Company reported total assets of $5.7 million , which includes its wholly owned image library and related transmedia IP carried at zero value. The sequential quarter over quarter increase of approximately $3 million in total assets primarily reflects an increase in cash from remaining proceeds of the Company’s equity offering during the quarter.
Following the underwritten public offering resulting in approximately $7.8 million in gross proceeds ( $7.1 million net proceeds) on September 11, 2020 , the Company significantly reduced its total liabilities from $15.5 million as of June 30, 2020 to $3.3 million as of September 30 , 2020. As Creatd has consistently carried little long-term debt since inception, the substantial portion of the decrease in liabilities was attributed to the conversion of notes, accrued interest, and payables totaling approximately $11,900,000 into the Company’s equity. Cash repayment of accrued payables and short-term debt totaling $3,600,000 accounted for the remainder of the current liability decrease.
As of September 30, 2020 , the Company’s non-current portion of debt totaled $578,000 , comprising $412,000 in the Government Payroll Protection Program (“PPP”) loan and $177,000 in operating leases payable. The company intends on requesting relief in accordance with SBA guidelines for the PPP loan. At September 30, 2020 the Company’s current liabilities totaled $2.7 million , which included approximately $174,000 in (mandatory) convertible notes, $105,000 in deferred revenue and unrecognized tax benefits, and $1.04 million in short term debt, of which approximately $660,000 is related to the acquisition of Seller’s Choice. The Company is currently in litigation regarding the note and continues to believe that the case lacks merit and has moved to dismiss. The company has an appearance scheduled for November 19, 2020 and expects no major events to occur in regard to this litigation for the next 12 months. In the event this case is not summarily dismissed, the Company intends to vigorously challenge it.
As a result of the underwritten public offering and the debt conversion, the Company’s shares of common stock outstanding increased from 3.3 million as of June 30, 2020 to 8.7 million as of September 30 , 2020. The Company’s fully diluted share count increased by approximately 8.07 million shares during the third quarter to approximately 12.4 million shares (inclusive of all options, warrants and convertible debt). The majority of the increase to the fully diluted share count was also due to the underwritten public offering and debt conversions, and includes 1.7 million share purchase warrants issued in conjunction with the offering, 900,000 warrants issued in conjunction with debt conversion, and 400,000 performance-based stock options granted to management of the Company that vest on April 1, 2021 and, as previously mentioned, were part of a three-year program. If all outstanding options ( $23.67 average strike price) and warrants ( $5.63 average strike price) were exercised for cash, the Company would receive approximately $17.5 million in additional capital.
As of December 31, 2019 , the Company had federal and state tax loss carry forwards of approximately $21.0 million , which expire through the fiscal year ending December 31, 2033 .
Third Quarter 2020 Conference Call and Webcast Details:
Date/Time : Tuesday, November 17, 2020 – 11:00 a.m. (Eastern Time)
Those interested in participating may access the webcast using the link below: https://event.on24.com/wcc/r/2830586/777DE409B84791B83212B43FD73A2CCB
It is recommended that participants join 15 minutes before the presentation is scheduled to begin. A recording of the webcast will be made available on the Company’s website following the session.
Contact: Press and Investor Relations
Rachel David
Head of Business Development and Communications
Creatd, Inc.
(201) 258-3770
rachel.david@creatd.com
About Creatd
Creatd, Inc. (Nasdaq CM: CRTD) empowers creators, brands, and entrepreneurs through technology and partnership. Its flagship technology platform is Vocal; Vocal provides creators of all shapes and sizes, from bloggers to podcasters, and more, with best-in-class storytelling tools, safe and curated communities, and the opportunity to monetize their content. With 34 owned and operated communities, Vocal enables creators to connect to their ideal audiences and to partner with the brands that want to reach those audiences. For more information, the content of which is not part of this press release:
Creatd: https://creatd.com ;
Creatd IR: https://investors.creatd.com ;
Vocal Platform: https://vocal.media ;
Investor Relations Contact: ir@creatd.com
Forward-Looking Statements
Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings.
∗∗∗ Financial Statements Follow ∗∗∗
|
Creatd, Inc.
|
|
Condensed Consolidated Balance Sheet
|
|
|
|
|
|
|
|
|
September 30, 2020
(unaudited)
|
|
December 31,
2019
|
|
Assets
|
|
|
|
|
Current Assets
|
|
|
|
|
Cash
|
$ 2,897,385
|
|
$ 11,637
|
|
Prepaid expenses
|
–
|
|
4,127
|
|
Account receivable, net
|
90,319
|
|
50,849
|
|
Note receivable – related party
|
11,450
|
|
11,450
|
|
Marketable securities
|
200,000
|
|
–
|
|
Total Current Assets
|
3,199,154
|
|
78,063
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
40,032
|
|
42,363
|
|
Intangible assets
|
992,455
|
|
1,087,278
|
|
Goodwill
|
1,035,795
|
|
1,035,795
|
|
Deposits and other assets
|
197,243
|
|
16,836
|
|
Operating lease right of use asset
|
258,249
|
|
311,711
|
|
Total Assets
|
$ 5,722,928
|
|
$ 2,572,046
|
|
|
|
|
|
Liabilities and Stockholders ‘ Equity (Deficit)
|
|
|
|
|
Current Liabilities
|
|
|
|
|
Accounts payable and accrued liabilities
|
$ 1,339,024
|
|
$ 1,763,222
|
|
Demand loan
|
50,000
|
|
225,000
|
|
Convertible Notes – related party, net of debt discount
|
–
|
|
20,387
|
|
Convertible Notes, net of debt discount and issuance costs
|
174,469
|
|
2,896,425
|
|
Current portion of operating lease payable
|
79,816
|
|
105,763
|
|
Notes payable, related party, net of debt discount
|
3,295
|
|
5,129,342
|
|
Notes payable, net of debt discount and issuance costs
|
990,122
|
|
660,000
|
|
Unrecognized tax benefit
|
68,000
|
|
68,000
|
|
Deferred revenue
|
37,421
|
|
50,691
|
|
Warrant liability
|
–
|
|
10,000
|
|
Total Current Liabilities
|
2,742,147
|
|
10,928,830
|
|
|
|
|
|
Non-current Liabilities:
|
|
|
|
|
Note payable
|
401,764
|
|
–
|
|
Operating lease payable
|
176,623
|
|
201,944
|
|
|
|
|
|
Total Non-current Liabilities
|
578,387
|
|
201,944
|
|
Total Liabilities
|
|
|
|
|
3,320,534
|
|
11,130,774
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Stockholders’ Equity (Deficit)
|
|
|
|
|
Series A Preferred stock, $0.001 par value,0 and 31,581 issued and outstanding respectively
|
–
|
|
–
|
|
Series B Preferred stock, $0.001 par value,0 and 8,063 issued and outstanding, respectively
|
–
|
|
–
|
|
Series D Preferred stock, $0.001, 0 and 914 shares issued and outstanding respectively
|
–
|
|
–
|
|
Common stock, $0.001 par value: 100,000,000 authorized shares; 8,662,745 issued and 8,653,395 outstanding as of September 30, 2020 and 3,059,646 issued and 3,006,362 outstanding at December 31, 2019
|
8,607
|
|
3,059
|
|
Additional paid-in capital
|
67,812,570
|
|
36,391,819
|
|
Accumulated deficit
|
(65,302,489)
|
|
(44,580,437)
|
|
Accumulated other comprehensive income (loan)
|
(28,790)
|
|
(5,995)
|
|
Less: Treasury stock, 9,350 and 53,283 shares, respectively
|
(87,560)
|
|
(367,174)
|
|
Total Stockholders ‘ Equity (Deficit)
|
2,402,394
|
|
(8,558,728)
|
|
Total Liabilities and Stockholders ‘ Equity (Deficit)
|
$ 5,722,928
|
|
$ 2,572,046
|
|
Creatd, Inc.
|
|
Condensed Consolidated Statements of Operations
|
|
(unaudited)
|
|
|
|
Three Months ended
September 30
|
|
Nine Months ended
September 30
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
|
|
|
|
|
|
|
|
|
Net revenues
|
|
$ 424,814
|
|
$ 91,386
|
|
$ 1,040,496
|
|
$ 132,901
|
|
Cost of revenues
|
|
–
|
|
–
|
|
–
|
|
–
|
|
Gross margin
|
|
424,814
|
|
91,386
|
|
1,040,496
|
|
132,901
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
Compensation
|
|
5,203,931
|
|
531,502
|
|
7,470,629
|
|
1,803,113
|
|
Consulting fees
|
|
739,503
|
|
412,394
|
|
2,291,609
|
|
810,025
|
|
Research and development
|
|
158,528
|
|
11,349
|
|
329,803
|
|
366,247
|
|
General and administrative
|
|
1,346,716
|
|
792,664
|
|
3,333,520
|
|
1,917,154
|
|
Total operating expenses
|
|
7,448,678
|
|
1,747,909
|
|
13,425,561
|
|
4,896,539
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
(7,023,864)
|
|
(1,656,532)
|
|
(12,385,065)
|
|
(4,763,638)
|
|
|
|
|
|
|
|
|
|
|
Other income (expenses)
|
|
|
|
|
|
|
|
|
|
Other income
|
|
437,657
|
|
–
|
|
515,442
|
|
–
|
|
Interest expense
|
|
(512,650)
|
|
(164,439)
|
|
(1,379,386)
|
|
(329,040)
|
|
Accretion of debt discount and issuance cost
|
|
(6,370,557)
|
|
(111,027)
|
|
(6,697,778)
|
|
(228,017)
|
|
Settlement of vendor liabilities
|
|
–
|
|
–
|
|
(126,087)
|
|
–
|
|
Gain on marketable securities
|
|
(17,495)
|
|
–
|
|
(7,453)
|
|
–
|
|
Loss on extinguishment of debt
|
|
(88,734)
|
|
(2,022)
|
|
(623,774)
|
|
(83,171)
|
|
Gain settlement of debt
|
|
–
|
|
–
|
|
470
|
|
–
|
|
Other income (expenses), net
|
|
(6,551,778)
|
|
(277,488)
|
|
(8,318,566)
|
|
(640,228)
|
|
|
|
|
|
|
|
|
|
|
Loss before income tax provision
|
|
(13,575,643)
|
|
(1,934,011)
|
|
(20,703,631)
|
|
(5,403,866)
|
|
|
|
|
|
|
|
|
|
|
Income tax provision
|
|
–
|
|
–
|
|
–
|
|
–
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ (13,575,643)
|
|
$ (1,934,011)
|
|
$ (20,703,631)
|
|
$ (5,403,866)
|
|
|
|
|
|
|
|
|
|
|
Deemed dividend
|
|
18,421
|
|
–
|
|
18,421
|
|
|
|
Inducement expense
|
|
–
|
|
–
|
|
–
|
|
(7,628)
|
|
Net loss attributable to common shareholders
|
|
(13,594,064)
|
|
(1,934,011)
|
|
(20,722,052)
|
|
(5,396,238)
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
Currency translation gain (loss)
|
|
5,735
|
|
–
|
|
(22,795)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
(13,569,908)
|
|
(1,934,011)
|
|
(20,726,426)
|
|
(5,396,238)
|
|
|
|
|
|
|
|
|
|
|
Per-share data
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share
|
|
$ (3.20)
|
|
$ (0.65)
|
|
$ (5.91)
|
|
$ (2.05)
|
|
Weighted average number of common shares outstanding
|
|
4,254,300
|
|
2,966,440
|
|
3,506,393
|
|
2,633,406
|
A new study by the University of Georgia has shown that while grown-ups exercise mostly to lose weight, children should exercise to build endurance, or how well their bodies can handle long periods of exercise. Physical education for children should be centered on motivating children to be active, educating them on the benefits of exercise and improving their physical skills.
According to the authors of the study, strengthening children’s cardiorespiratory endurance should be the main goal in exercise for children. Even children who are overweight can still achieve the recommended one hour of moderate to vigorous physical activity every day. The BMI of a person is measured to find out if he or she is overweight, obese or normal weight. The measurement is said to indicate that children who are more active in PE are more likely to remain active after school.
Lead author of the study, associate professor in the Mary Frances Early College of Education Sami Yli-Piipari, explained that the research had demonstrated that even in young children, those who are fitter with regard to cardiorespiratory endurance took part in more intense physical activities. He also stated that children who were a little overweight could still be relatively fit and that the weight didn’t really matter.
The study involved 450 kids, between the ages of 10-12, who participated in one and a half hours of mandatory physical education (PE) each week. During the day, the children wore an accelerometer on their right hip to record the total physical activity for a week. Additionally, simple tests, such as being able to do a crunch or a modified or regular push-up, were used to find out the children’s mastery of physical skills. The researchers also evaluated whether students took part in PE because it was mandatory or because they enjoyed it.
Yli-Piipari added that PE mattered, as the activities helped students not only learn skills but also presented them with the opportunity to do something active at a higher level than they normally might after the school day. The study was conducted in Finland, as students in that country have more time allotted to PE classes as their fellow American students. Finnish PE classes focus on the significance of exercise and how to include it into students’ daily activities.
As prior research had already shown, boys tended to be more active when compared to girls. Surprisingly though, motor skills and muscle strength did not depend on activity levels. The researchers discovered that motivation did not play a role in whether a student wanted to take part in PE or whether they enjoyed the PE classes. Those who were generally less active in their down time were found to be children who didn’t take part in after-school activities.
AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biomedical company worthy of your attention. The company is in the business of using recombinant proteins to come up with novel treatments targeting gastrointestinal conditions.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- HempFusion Wellness, Inc. is a health and wellness company developing the power of whole-food hemp nutrition through more than 40 products currently on store shelves
- The company is focused on industry safety and quality standards through regulatory compliance, and is currently participating in a real world consumer study to establish the safety of daily cannabidiol (“CBD”) use in regard to liver function
- HempFusion has filed a preliminary prospectus for a planned initial public offering of its stock in Canada and a listing on the Toronto Stock Exchange
- Despite a reduction in hemp farm acreage this year following last year’s glut, market watchers anticipate the industrial hemp market is expected to reach $22 billion by 2022
The U.S. election this month demonstrated the lasting potential of the market for cannabis-derived products when five states joined the march toward legalizing marijuana for recreational or medicinal uses (https://nnw.fm/41UKq). Despite a variety of challenges that plagued the nascent hemp industry in 2019 as well as the contentious societal debates over the COVID-19 pandemic’s impact on everyday life and the choices for president, cannabis’ hemp and marijuana offshoots seem to have transcended the upheaval that has defined 2020.
Denver-based HempFusion Wellness has continued to build its own movement toward market success in the cannabis wellness industry, developing 46 products that are currently on shelves while establishing the second-largest cash position in its sector without debt. And in October the company announced a preliminary prospectus with the securities regulatory authorities in Canada, excepting the Quebec province, for a proposed initial public offering of common shares and listing on the Toronto Stock Exchange that makes HempFusion the first US-based cannabidiol (“CBD”) company to apply to list on the TSX (https://nnw.fm/LTOfk).
HempFusion Wellness has invested heavily in regulatory compliance in order to meet and exceed the safety and quality standards established not only by government officials, but selective consumers and retailers as well. As a member of the U.S. Hemp Roundtable, the company works with other coalition members in advancing the safety of hemp and CBD products.
The company’s focus on regulatory compliance has in turn opened doors to major food and drug mass market retailers. HempFusion has its eye on five channels — natural health retail outlets, Internet-based commerce, big box chains and other mass markets, doctor / care provider referrals and convenience stores.
HempFusion’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex products present solutions for basic, specific needs such as sleep, energy and stress. Its offerings include tinctures and capsules, as well as FDA listed over-the-counter (“OTC”) products designed to combat pain, eczema, acne and skin aging, and wounds.
HempFusion is one of 12 companies working to capture real world evidence from consumers on how they use CBD products and how their bodies react to those products, with a primary focus on whether daily use is safe for the liver in response to questions raised by the U.S. Food and Drug Administration (https://nnw.fm/C5axg).
“We believe this real world evidence is important to the FDA and could be used to guide policy moving forward,” Patrick McCarthy, the CEO of life sciences researcher ValidCare, which is conducting the scientific study, stated.
Licensed hemp farm acreage decreased on a year-over-year basis in 2020 for the first time since the 2014 Farm Bill established a national hemp pilot program, according to industry watchers (https://nnw.fm/y3z2h). The downward movement was driven by regulatory uncertainty and a vast oversupply of hemp last year in the wake of the previous winter’s updating of the 2014 bill to provide broader legalization to hemp as an agricultural commodity. It is important to note, HempFusion is not a cultivator and is instead focused on product R&D, increased distribution and consumer safety. Nevertheless, Brightfield Group has projected the hemp CBD market to reach $22 billion by 2022 (https://nnw.fm/3Z5Fi).
For more information, visit the company’s website at www.HempFusion.com/Corporate-Information.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://nnw.fm/HempFusion
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
